

**Diaceutics PLC**  
("Diaceutics" or the "Company")

**H1 2025 Trading Update**

**Revenue growth of 22% on a constant currency basis to £14.6 million in H1 2025 representing a 3-year CAGR of 25%**

*Continued strong commercial momentum in H1 2025*

*Order book of £29.4 million with £8.8 million already contracted for H2 2025 delivery*

*Annual Recurring Revenue (ARR) up 16% to £16.4 million, with recurring revenue now representing 70% of total H1 revenues*

*17% growth in number of customer therapeutic brands Diaceutics is working with*

*New enterprise-wide agreement signed, bringing total to eight, representing £10.1 million in ARR*

*Diaceutics continues to demonstrate its ability to be the primary commercialisation partner for pharma and biotech companies launching precision medicines*

*Strong balance sheet with no debt and cash of £10.4 million*

**New York, Belfast and London, 22 July 2025 - [Diaceutics PLC](#)** (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today provides a trading update for the half year to 30 June 2025. The Company delivered another period of strong organic growth, platform expansion, and commercial execution, supporting continued confidence in meeting growth and profitability targets for the year ending 31 December 2025 ("FY 2025").

**Ryan Keeling, Diaceutics' Chief Executive Officer, commented:** *"I am extremely pleased to report another period of strong operational and commercial execution, marked by double-digit organic revenue growth, expanding customer adoption and increased recurring revenue visibility. Despite macro-economic uncertainties globally, our customers remain active as they seek our help to improve patient access to therapy, capture lost revenue and increase profitability. Our continued growth demonstrates the significant value our customers place on our solutions, reflected by the increasing number of therapeutic brands we are working with. Our deepening engagement with enterprise clients, consistent growth in therapeutic brand count, and strong pipeline coverage into the historically stronger second half of the year, gives us confidence in delivering against both growth and profitability targets for the full year."*

**Trading Update to 30 June 2025**

Revenues grew 18% to £14.6 million in H1 2025 (H1 2024: £12.3 million), 22% growth on a constant currency basis, delivering a 3-year compound H1 growth rate of 25%.

The Company continues to improve the sustainability and visibility of its revenues, with ARR growing 16% to £16.4 million as at 30 June 2025 (£14.2 million at 30 June 2024), with recurring revenues in H1 2025 representing approximately 70% of total revenue in the year (H1 2024: 55% of total revenue).

As at 30 June 2025, the order book that will be realised as revenue in H2 2025 was approximately £8.8 million (H2 2024: £8.9 million) and, including weighted pipeline, gives circa 79% visibility on FY 2025 analyst consensus estimates\* (H1 2024: 71% visibility on FY 2024 revenue). H1 2025 also saw the Company deliver positive Adjusted EBITDA\*\*. These metrics are in line with the Board's expectations at this point in the year, providing good levels of revenue visibility and confidence in profitability expectations as the Company enters the historically stronger second half of the year.

Diaceutics secured a new multi-year enterprise-wide engagement with a total ARR of £0.8 million in H1 2025.

This brings the total number of enterprise-wide engagements secured to eight, across 35 therapeutic brands, with a total ARR of £10.1 million as at 30 June 2025 (seven enterprises engagements across 31 therapeutic brands with a total ARR of £10.6 million at 30 June 2024).

DXRX platform adoption by pharma and biotech customers continues to drive business momentum with Diaceutics consistently working with 18 of the top 20 global pharma companies across 53 therapeutic brands in H1 2025. In H1 2025 to date, Diaceutics has worked with a total of 74 therapeutic brands across 43 customers (H1 2024: 44 customers and 63 therapeutic brands).

Diaceutics remains debt free and cash at 30 June 2025 was £10.4 million (31 December 2024: £12.7 million) which is in line with the Board's expectations, supporting continued investment in product innovation and commercial growth.

#### Outlook

- Global pharma and biotech customers are continuing to accelerate their shift to precision medicine to improve patient access, capture lost revenue and increase profitability
- New enhanced technologies and product offerings across the platform are delivering continued operational leverage
- Commercial pipeline and platform expansion expected to support continued margin improvement in H2 2025
- Future expansion of the market opportunities outside of precision medicine being explored
- The Board reaffirms its confidence in the Company's strategy, operational performance and ability to continue delivering high-quality, recurring revenue growth and meeting FY 2025 growth and profitability targets

*All numbers stated are approximate and subject to audit.*

*\*Analyst consensus estimates for FY 2025 revenue is £40 million and Adjusted EBITDA is £7.0 million.*

*\*\* EBITDA is earnings before interest, tax, depreciation and amortisation. Adjusted EBITDA removes share-based payment charges and once-off exceptional items.*

#### Enquiries:

##### Diaceutics PLC

Ryan Keeling, Chief Executive Officer  
Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500  
[investorrelations@diaceutics.com](mailto:investorrelations@diaceutics.com)

##### Canaccord Genuity Limited (Nomad & Broker)

Simon Bridges, Andrew Potts, Harry Rees

Tel: +44 (0)20 7523 8000

#### About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

Prior to publication the information communicated in this announcement was deemed by the Company to constitute inside information for the purposes of article 7 of the Market Abuse Regulations (EU) No 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations No 2019/310 ('MAR'). With the publication of this announcement, this information is now considered to be in the public domain. The person responsible for making this announcement on behalf of the Company is Nick Roberts, Chief Financial Officer.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TSTFLFLSLDILFIE